Samsung Bioepis and Momenta Highlighted Two Posters of Aflibercept Biosimilars at AAO 2022
Shots:
- The company highlighted 2 posters of the P-III trials evaluating SB15 (developed by Samsung Bioepis) & MYL-1701P (developed by Momenta & Viatris) vs Eylea in a ratio (1:1) in 449 treatment-naive nAMD patients & 355 patients
- In a 32wk. analysis of SB15, the 1EPs were found to be equivalent with no new safety signals, and incidence & severity of TEAEs b/w 2 products were similar ~32wk. while immunogenicity & PK profiles were also similar
- The (INSIGHT) Study on MYL-1701P showed the therapeutic equivalence b/w drugs, TEAEs were comparable for the biosimilar & reference product with no differences regarding antidrug Abs, patients who had gains and losses in visual acuity were similar b/w the treatment arms & was safe & well tolerated
Ref: Biosimilars | Image: Samsung Bioepis
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
